Therefore, LJ4827 is a novel anticancer therapeuticfor selectively impeding cancer mitosis through potent HASPIN inhibition,and simultaneous HASPIN and PLK1 interference is a promising therapeuticstrategy for lung cancer. Here, PLK1 is linked to lung carcinoma.